Vivos Therapeutics, Inc. (VVOS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 13 | 17 | 16 | 14 | 15 | 17 | 21 | 24 |
| Operating profit | $m | -20 | -23 | ||||||
| Net profit | $m | -12 | -20 | -24 | -14 | -11 | -21 | -26 | -11 |
| EPS reported | $ | -2.06 | -2.06 | ||||||
| Operating cashflow per share | $ | -1.49 | -1.19 | ||||||
| Capex per share | $ | 0.23 | 0.05 | ||||||
| FCF per share | $ | -1.71 | -1.25 | ||||||
| Free cash flow | $m | -18 | -18 | ||||||
| Net debt | $m | 7 | 10 | ||||||
| Book value equity | $m | -1 | -4 | ||||||
| Book value per share | $ | -0.15 | -0.22 | ||||||
| Number of shares | m | 10.27 | 17.68 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -14.00 | -5.47 | ||||||
| P/S LTM | x | 1.20 | 1.00 | ||||||
| P/FCF LTM | x | -1.18 | -1.16 | ||||||
| EV/EBITDA LTM | x | -1.62 | -1.39 | ||||||
| EV/Sales LTM | x | 1.85 | 0.62 | ||||||
| Earnings Yield LTM | % | -1.02% | -5.35% | ||||||
| FCF Yield | % | -84.41% | -85.94% | ||||||
| Quality | |||||||||
| ROE | % | +1424.8% | -2239.2% | ||||||
| ROIC | % | -1.23% | -1.49% | ||||||
| Operating margin | % | -1.14% | -1.15% | ||||||
| Gross margin | % | +60.44% | +59.48% | ||||||
| FCF/Sales | % | -100.92% | -93.25% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +16.05% | +39.05% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.30 | -1.48 | ||||||
| Net Debt/EBITDA | x | -0.58 | -0.43 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +42.30% | +4.09% | ||||||
| Net debt/Equity | x | -4.56 | -2.72 | ||||||
| Gross debt/equity | x | -9.06 | -3.18 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free